Dabigatran versus Warfarin in Patients with Atrial Fibrillation.

---

Connolly S. J., Ezekowitz M. D., Yusuf S., Eikelboom J., Oldgren J., Parekh A., ...More

NEW ENGLAND JOURNAL OF MEDICINE, vol.361, no.12, pp.1139-1151, 2009 (SCI-Expanded, Scopus)

• Publication Type: Article / Article
• Volume: 361 Issue: 12
• Publication Date: 2009
• Doi Number: 10.1056/nejmoa0905561
• Journal Name: NEW ENGLAND JOURNAL OF MEDICINE
• Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
• Page Numbers: pp.1139-1151
• Open Archive Collection: AVESIS Open Access Collection
• Ankara University Affiliated: No

Abstract

Background: Warfarin reduces the risk of stroke in patients with atrial fibrillation but increases the risk of hemorrhage and is difficult to use. Dabigatran is a new oral direct thrombin inhibitor.